Selinexor

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Myelofibrosis · Phase 3 · investigational in the US · under FDA reviewEndometrial Cancer · Phase 3 · investigational in the US

Also approved (1)
EU
  • NEXPOVIO is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Product first approved 2021EMA

Company guidance: topline data expected second half of 2026 (NCT04562389; Karyopharm Therapeutics, 13 Aug 2026). “Topline data from the Phase 2 SENTRY-2 60 mg cohort expected in the second half of 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
Endometrial Cancer
Multiple Myeloma
NCT04939142 · Antengene Corporation
2021-07-12 – 2025-10-30 · Relapsed or Refractory Multiple Myeloma
What this study did
Myelofibrosis
Other / comorbidity
NCT06613035 · Institute of Hematology & Blood Diseases Hospital, China
2024-09-30 – 2027-09-30 · Acute Myeloid Leukemia
What this study did
NCT05726110 · Shanxi Bethune Hospital
2023-01-29 – 2024-12-31 · Relapsed or Refractory Acute Myeloid Leukemia
What this study did
NCT04534725 · Peter MacCallum Cancer Centre, Australia
2020-12-17 – 2023-04-19 · Cancer, Covid19, Respiratory Viral Infection
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT07369739 · Beijing Friendship Hospital
2026-01-01 – 2028-01-01 · Lymphohistiocytosis, EBV, CAEBV
What this study did
NCT04442022 · Karyopharm Therapeutics Inc
2020-09-03 – 2026-12 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT05822050 · The First Hospital of Jilin University
2023-06-01 – 2025-06-30 · PTCL Patients Who Achieved Complete Response From Frontline Treatment
What this study did
NCT02606461 · Karyopharm Therapeutics Inc
2016-01-04 – 2021-10-26 · Dedifferentiated Liposarcoma
What this study did
Phase 2 (84)
Endometrial Cancer
NCT07832227 · Dana-Farber Cancer Institute
2026-12-01 – 2029-08-01 · Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer
What this study did
NCT04998760 · Qi Zhou
2021-08-03 – 2024-04-09 · 1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
What this study did
Multiple Myeloma
NCT05530421 · University of Miami
2023-03-26 – 2030-03-26 · Relapsed and Refractory Multiple Myeloma
What this study did
NCT06744894 · Navy General Hospital, Beijing
2025-01-01 – 2030-01-01 · Multiple Myeloma
What this study did
NCT04717700 · Ida Bruun Kristensen
2021-08-18 – 2029-06-01 · Multiple Myeloma
What this study did
NCT04661137 · Hackensack Meridian Health
2021-03-16 – 2028-02 · Multiple Myeloma
What this study did
NCT04414475 · Karyopharm Therapeutics Inc
2020-07-01 – 2028-01 · Multiple Myeloma, Refractory
What this study did
NCT06822972 · Duke University
2025-08-22 – 2027-12-31 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT04756401 · Academic and Community Cancer Research United
2022-12-08 – 2027-12-30 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT06169215 · National Cancer Institute (NCI)
2024-07-23 – 2027-09-23 · Multiple Myeloma
What this study did
NCT05820763 · Washington University School of Medicine
2024-01-05 – 2027-01-31 · Multiple Myeloma, Myeloma-Associated Amyloidosis
What this study did
NCT04925193 · University of Colorado, Denver
2021-11-18 – 2026-11 · Multiple Myeloma in Relapse
What this study did
NCT05900882 · The First Affiliated Hospital with Nanjing Medical University
2022-07-15 – 2026-08-30 · Multiple Myeloma
What this study did
NCT03589222 · PETHEMA Foundation
2018-07-15 – 2026-08 · Refractory Multiple Myeloma
What this study did
NCT04782687 · US Oncology Research
2021-09-10 – 2026-05-31 · Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
What this study did
NCT05597345 · University of Rochester
2023-08-21 – 2025-12-31 · Smoldering Multiple Myeloma
What this study did
NCT04941937 · Juan Du
2022-01-27 – 2025-12-30 · Multiple Myeloma
What this study did
NCT05478993 · Peking University People's Hospital
2022-10-12 – 2025-07-10 · Multiple Myeloma
What this study did
NCT04877275 · Chunyan Sun, MD
2021-05-21 – 2024-12-30 · Multiple Myeloma
What this study did
NCT06212596 · University of Leeds
2018-07-16 – 2023-11-14 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT04843579 · Weill Medical College of Cornell University
2021-12-29 – 2022-12-30 · Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
What this study did
NCT05170789 · Tulane University School of Medicine
2022-04-27 – 2022-04-27 · Relapsed Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT03944057 · Antengene Corporation
2019-09-02 – 2022-02-25 · Relapse/Refractory Multiple Myeloma
What this study did
NCT02628704 · Karyopharm Therapeutics Inc
2015-12 – 2018-06 · Multiple Myeloma
What this study did
Myelofibrosis
NCT07447817 · John Mascarenhas
2026-10-23 – 2030-05-24 · Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
What this study did
NCT05980806 · Karyopharm Therapeutics Inc
2024-04-22 – 2028-10 · Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
What this study did
NCT04562870 · Karyopharm Therapeutics Inc
2021-03-17 – 2026-09 · Myelofibrosis
What this study did
NCT03627403 · University of Utah
2019-05-10 – 2025-03-05 · Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
What this study did
Other / comorbidity
NCT05983276 · Loyola University
2023-11-16 – 2031-08-28 · Ovarian Cancer
What this study did
NCT07574528 · Sun Yat-sen University
2026-05-06 – 2031-05-06 · NKTCL
What this study did
NCT07276698 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
2025-12-30 – 2029-12-30 · NK T-Cell Lymphoma
What this study did
NCT05985161 · Memorial Sloan Kettering Cancer Center
2023-08-01 – 2029-08-01 · Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
What this study did
NCT07554482 · Beijing Tongren Hospital
2026-05-15 – 2029-04-30 · Extranodal NK/T-cell Lymphoma
What this study did
NCT07405255 · Ruijin Hospital
2026-01-30 – 2028-12-30 · Central Nervous System Lymphoma
What this study did
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT06652139 · Ruijin Hospital
2024-11-01 – 2028-11-01 · Diffuse Large B Cell Lymphoma
What this study did
NCT07743957 · Beijing Anzhen Hospital
2026-07-13 – 2028-06-01 · Light-chain Cardiac Amyloidosis
What this study did
NCT06517511 · Sun Yat-sen University
2024-08-01 – 2028-04 · Diffuse Large B Cell Lymphoma
What this study did
NCT06813079 · University Health Network, Toronto
2025-04-07 – 2028-02-17 · Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor
What this study did
NCT06765928 · Ruijin Hospital
2025-01-01 – 2028-01-01 · MDS, AML, Adult
What this study did
NCT07437170 · The Children's Hospital of Zhejiang University School of Medicine
2024-01-01 – 2027-12-31 · Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia
What this study did
NCT06062641 · Ruijin Hospital
2023-10-30 – 2027-09-30 · Relapsed or Refractory B-cell Lymphoma
What this study did
NCT07204041 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-08-01 – 2027-08-02 · Langerhans Cell Histiocytosis (LCH)
What this study did
NCT06573138 · Ruijin Hospital
2024-09-01 – 2027-07-01 · Lymphoma, Extranodal NK-T-Cell
What this study did
NCT06573151 · Ruijin Hospital
2024-09-01 – 2027-07-01 · Lymphoma
What this study did
NCT05333458 · National Cancer Institute (NCI)
2022-08-29 – 2027-05-01 · Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
What this study did
NCT05736965 · Shanghai Tong Ren Hospital
2023-02-20 – 2027-04-30 · AML, Adult
What this study did
NCT02835222 · Wake Forest University Health Sciences
2018-02-02 – 2027-04-18 · Untreated Adult Acute Myeloid Leukemia
What this study did
Phase 1/2 (39)
Multiple Myeloma
NCT07479979 · Natalie Callander
2026-05-21 – 2029-07 · Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT04764942 · Mayo Clinic
2021-05-06 – 2027-12-17 · Recurrent Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT02343042 · Karyopharm Therapeutics Inc
2015-10 – 2027-04 · Multiple Myeloma
What this study did
NCT05422027 · Xia Zhongjun
2022-07-25 – 2025-12-31 · Multiple Myeloma
What this study did
NCT03732703 · Multiple Myeloma Research Consortium
2019-04-01 – 2024-12-31 · Relapsed Refractory Multiple Myeloma
What this study did
NCT04891744 · Li Zheng
2021-07-06 – 2024-12-30 · Multiple Myeloma
What this study did
NCT02780609 · H. Lee Moffitt Cancer Center and Research Institute
2017-07-20 – 2021-02-23 · Multiple Myeloma
What this study did
NCT02186834 · H. Lee Moffitt Cancer Center and Research Institute
2014-09-23 – 2018-03-14 · Multiple Myeloma
What this study did
NCT02389543 · Karyopharm Therapeutics Inc
2015-07 – 2018-02 · Multiple Myeloma
What this study did
Other / comorbidity
NCT06239272 · St. Jude Children's Research Hospital
2024-03-27 – 2037-06 · Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma, Angiosarcoma, Osteosarcoma, Extraskeletal, Dedifferentiated Liposarcoma, Myxoid Liposarcoma, Pleomorphic Liposarcoma, Myxoid Pleomorphic Liposarcoma, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, Malignant Tenosynovial Giant Cell Tumor of Soft Tissue, Epithelioid Hemangioendothelioma, Glomus Tumor, Inflammatory Leiomyosarcoma, Leiomyosarcoma, Ossifying Fibromyxoid Tumor, Malignant, Myoepithelioma, Synovial Sarcoma, Epithelioid Sarcoma, Perineurioma, Malignant, Clear Cell Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Granular Cell Tumor, Malignant, Melanotic Malignant Nerve Sheath Tumor, Malignant Peripheral Nerve Sheath Tumor, Perivascular Epithelioid Tumor, Malignant, Intimal Sarcoma, Myoepithelial Carcinoma, Undifferentiated Sarcoma, Pleomorphic Sarcoma, Undifferentiated, Round Cell Sarcoma, Undifferentiated, NTRK-Rearranged Spindle Cell Neoplasm, Phosphaturic Mesenchymal Tumor, Malignant, Round Cell Sarcoma, Well Differentiated Liposarcoma, Giant Cell Tumor of Soft Parts NOS, Low Grade Myofibroblastic Sarcoma, Dermatofibrosarcoma Protuberans, Fibrosarcomatous
What this study did
NCT07706959 · Ruijin Hospital
2026-07 – 2029-07 · Peripheral T-cell Lymphoma (PTCL)
What this study did
NCT06552559 · Samsung Medical Center
2024-05-01 – 2028-12-30 · B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases
What this study did
NCT06556199 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-08-31 – 2028-08-31 · Relapsed/Refractory Primary Central Nervous System Lymphoma
What this study did
NCT05675813 · Ruijin Hospital
2023-02-13 – 2028-07-15 · Peripheral T Cell Lymphoma
What this study did
NCT06966154 · Fudan University
2025-05-26 – 2028-05-30 · Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL
What this study did
NCT07779031 · Liping Dou
2025-05-01 – 2028-05-01 · Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
What this study did
NCT05035745 · National University Hospital, Singapore
2021-03-01 – 2027-11 · Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers
What this study did
NCT05099003 · National Cancer Institute (NCI)
2022-05-31 – 2027-09-30 · Malignant Glioma
What this study did
NCT05432804 · National Cancer Institute (NCI)
2023-03-20 – 2027-06-30 · Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
What this study did
NCT03147885 · Barbara Ann Karmanos Cancer Institute
2017-06-20 – 2027-06-25 · Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
What this study did
NCT06559553 · Mingzhi Zhang
2024-09-01 – 2026-12-31 · NKTCL, Selinexor
What this study did
NCT05698147 · Tong Chen, MD
2023-08-03 – 2026-12-31 · Central Nervous System Lymphoma
What this study did
NCT05577364 · Sun Yat-sen University
2022-11-01 – 2026-02-28 · EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
What this study did
NCT05498636 · The Affiliated Hospital of Qingdao University
2022-10-01 – 2025-12-31 · DLBCL
What this study did
NCT04607772 · Karyopharm Therapeutics Inc
2020-11-18 – 2025-12 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT06449482 · Institute of Hematology & Blood Diseases Hospital, China
2023-05-05 – 2025-03-30 · Acute Myeloid Leukemia, Adult
What this study did
NCT05265975 · Antengene Corporation
2022-04-07 – 2024-12-31 · Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
What this study did
NCT04256707 · Karyopharm Therapeutics Inc
2020-02-09 – 2024-07-31 · Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
What this study did
NCT05975944 · Tianjin Medical University Cancer Institute and Hospital
2023-09 – 2024-05 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT04856189 · Mamta Parikh
2021-04-08 – 2024-02-13 · Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma
What this study did
NCT04421378 · Karyopharm Therapeutics Inc
2020-06-08 – 2023-07-03 · Glioblastoma Multiforme
What this study did
NCT04138381 · Grupo Espanol de Investigacion en Sarcomas
2019-08-16 – 2023-04-16 · Maximum Tolerated Dose, GIST, Metastatic Adult Soft Tissue Sarcoma, Drug Toxicity, Drug Use
What this study did
NCT02178436 · Mohammed Najeeb Al Hallak
2014-10-31 – 2023-04-05 · Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
What this study did
NCT03095612 · University of Texas Southwestern Medical Center
2018-03-22 – 2023-03-03 · Non-small Cell Lung Cancer
What this study did
NCT02416908 · Washington University School of Medicine
2015-06-16 – 2019-06-21 · Acute Myeloid Leukemia
What this study did
NCT02530476 · M.D. Anderson Cancer Center
2015-12-08 – 2019-04-08 · Leukemia, Acute Myeloid Leukemia
What this study did
NCT02536495 · Erin Bertino
2015-09 – 2018-12 · Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
What this study did
NCT05177276 · Martin Gutierrez
2014-09 – 2015-09 · Solid Tumor Malignancy
What this study did
NCT02367690 · Karyopharm Therapeutics Inc
2015-01 – 2015-09 · Diabetic Foot Ulcers
What this study did
Phase 1 (43)
Endometrial Cancer
NCT02269293 · Memorial Sloan Kettering Cancer Center
2014-10-13 – 2021-04-20 · Ovarian Cancer, Endometrial Cancer
What this study did
Multiple Myeloma
NCT07200102 · Washington University School of Medicine
2026-03-17 – 2031-03-31 · Multiple Myeloma
What this study did
NCT06225310 · Oncotherapeutics
2024-08-06 – 2027-05-01 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT04640779 · Mayo Clinic
2021-02-08 – 2025-11-19 · Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma
What this study did
NCT02199665 · University of Chicago
2014-06-12 – 2025-10-25 · Refractory Multiple Myeloma
What this study did
NCT05201118 · Chunrui Li
2022-01-01 – 2023-12-31 · Extramedullary Multiple Myeloma
What this study did
NCT04519476 · Oncotherapeutics
2020-11-01 – 2023-12-29 · Refractory Multiple Myeloma
What this study did
NCT02831686 · Memorial Sloan Kettering Cancer Center
2016-07 – 2020-11-19 · Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT05952687 · St. Jude Children's Research Hospital
2024-03 – 2032-08 · Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor of CNS, CNS Tumor
What this study did
NCT07094464 · Daihong Liu
2025-06-01 – 2028-12-30 · TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
What this study did
NCT04898894 · St. Jude Children's Research Hospital
2021-11-15 – 2027-09 · Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
What this study did
NCT02091245 · Dana-Farber Cancer Institute
2014-03 – 2026-12 · Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis
What this study did
NCT04216329 · National Cancer Institute (NCI)
2020-07-07 – 2026-07-09 · Gliosarcoma, Newly Diagnosed, Glioblastoma
What this study did
NCT04595994 · Grupo Espanol de Investigacion en Sarcomas
2020-09-02 – 2026-05-31 · Sarcoma,Soft Tissue
What this study did
NCT04811196 · University Health Network, Toronto
2021-03-29 – 2025-05-15 · Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Leiomyosarcoma, Endometrial Stromal Sarcoma
What this study did
NCT04850755 · National University Hospital, Singapore
2021-03-08 – 2025-03-17 · Advance Solid Malignancies, Metastatic Solid Malignancies
What this study did
NCT02323880 · Children's Oncology Group
2015-10-30 – 2024-12-31 · Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
What this study did
NCT02419495 · M.D. Anderson Cancer Center
2015-06-26 – 2024-09-16 · Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
What this study did
NCT03955783 · Sanjay Mohan
2019-06-21 – 2024-09-01 · Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
What this study did
NCT04984330 · Weill Medical College of Cornell University
2021-12 – 2024-06 · Amyloid, Amyloidosis, AL Amyloidosis
What this study did
NCT05354362 · Antengene Corporation
2022-03-02 – 2023-02-08 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT05093608 · H. Lee Moffitt Cancer Center and Research Institute
2021-11-03 – 2022-10-12 · Hepatocellular Carcinoma
What this study did
NCT02303392 · Jennifer Woyach
2015-06-09 – 2022-04-18 · Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
What this study did
NCT02471911 · Weill Medical College of Cornell University
2015-12-11 – 2021-10-14 · Diffuse Large B-Cell Lymphoma
What this study did
NCT02741388 · The Lymphoma Academic Research Organisation
2016-10 – 2021-09-29 · B-cell Lymphoma
What this study did
NCT03042819 · University Health Network, Toronto
2017-05-16 – 2021-06-30 · Soft Tissue Sarcoma
What this study did
NCT02403310 · H. Lee Moffitt Cancer Center and Research Institute
2015-06-18 – 2021-02-01 · Leukemia, Acute Myeloid Leukemia, AML
What this study did
NCT03880123 · Matthew Ingham
2020-11 – 2020-11-24 · Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
What this study did
NCT03212937 · National Cancer Centre, Singapore
2016-07-01 – 2020-11 · Peripheral T-cell Lymphoma
What this study did
NCT02485535 · University of Chicago
2015-09-04 – 2020-07 · Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
What this study did
NCT02078349 · National University Hospital, Singapore
2014-02 – 2020-03-20 · Solid Tumors
What this study did
NCT03661515 · PETHEMA Foundation
2018-07-17 – 2019-10-15 · Acute Myeloid Leukemia
What this study did
NCT02573363 · University of Chicago
2015-10-07 – 2019-05-03 · Acute Myeloid Leukemia
What this study did
NCT02120222 · Kari Kendra
2014-08-22 – 2018-04-08 · Recurrent Melanoma
What this study did
NCT02299518 · Alice Mims
2015-05-18 – 2018-03-06 · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
What this study did
NCT02137356 · Sheba Medical Center
2014-12 – 2017-09 · Rectal Neoplasms
What this study did
NCT02384850 · GSO Global Clinical Research BV
2015-03 – 2017-03-09 · Colorectal Neoplasm
What this study did
NCT02093403 · Bhavana Bhatnagar
2014-03 – 2016-11-26 · Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
What this study did
NCT01896505 · Karyopharm Therapeutics Inc
2013-07-30 – 2016-10-21 · Sarcoma
What this study did
NCT01607905 · Karyopharm Therapeutics Inc
2012-06-18 – 2016-03-15 · Solid Tumor
What this study did
NCT02283359 · H. Lee Moffitt Cancer Center and Research Institute
2014-12 – 2016-01 · Esophageal Cancer, Gastric Cancer
What this study did
NCT02212561 · St. Jude Children's Research Hospital
2014-08 – 2015-12 · Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
What this study did
NCT01607892 · Karyopharm Therapeutics Inc
2012-07-23 – 2015-10-13 · Hematological Malignancies
What this study did
Phase 4 (1)
Other / comorbidity
NCT05786989 · Chongqing University Cancer Hospital
2023-02-28 – 2024-09-30 · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
What this study did
Early phase / not applicable (7)
Other / comorbidity
NCT06265545 · Institute of Hematology & Blood Diseases Hospital, China
2024-02-22 – 2028-06-30 · AML, Refractory, Relapsed
What this study did
NCT06853678 · Tianjin Medical University Cancer Institute and Hospital
2025-02-28 – 2027-03-01 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT05805072 · The First Affiliated Hospital of Soochow University
2023-05-01 – 2024-06-30 · Relapsed/Refractory AML
What this study did
NCT02069730 · University Health Network, Toronto
2014-06 – 2023-06 · Salivary Gland Cancer, Metastatic, Advanced, Recurrent
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Multiple Myeloma
NCT07569757 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-06 – 2030-12 · Multiple Myeloma
What this study did
NCT07623798 · Innovent Biologics (Suzhou) Co. Ltd.
2026-06-11 – 2029-12-31 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07138209 · Qilu Pharmaceutical Co., Ltd.
2025-11-07 – 2029-12 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT07579234 · Shandong New Time Pharmaceutical Co., LTD
2026-01-25 – 2029-01-25 · Relapsed or Refractory Multiple Myeloma (RRMM)
What this study did
NCT05675319 · Universitätsklinikum Hamburg-Eppendorf
2023-03-03 – 2025-03-21 · Multiple Myeloma
What this study did
Other / comorbidity
NCT07011056 · Chengdu Zenitar Biomedical Technology Co., Ltd
2025-07-18 – 2029-06-30 · Recurrent and Refractory Diffuse Large B-cell Lymphoma
What this study did

Competitive landscape

Other XPO1 (exportin-1) drugs

Eltanexor. Compare all 2 XPO1 (exportin-1) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Endometrial Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Selinexor: this drugPhase 3Small moleculeXPO1 (exportin-1)not yet gradedNo reviewed efficacy summary in this indication
DostarlimabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 3Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
SerabelisibPhase 2Small moleculePI3K alpha (inhibitor)Weak signalNo reviewed efficacy summary in this indication
IMGN-151Phase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(48 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Selinexor to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Phase 2/3Relapsed/Refractory Diffuse Large B-cell LymphomaActive not recruiting
Est. primary completion 2026-12 · NCT04442022 · CT.gov ↗
What to watch
Phase 1/2NKTCL, SelinexorRecruiting
Est. primary completion 2026-12-01 · NCT06559553 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2026-12-31 · NCT06822972 · CT.gov ↗
What to watch
Phase 2LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT02436707 · CT.gov ↗
What to watch
2027 (25)
January 2027 (2)
Phase 2Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2027-01 · NCT06517511 · CT.gov ↗
What to watch
Phase 2/3Lymphohistiocytosis, EBV, CAEBVRecruiting
Est. primary completion 2027-01-01 · NCT07369739 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2027-04-01 · NCT06225310 · CT.gov ↗
What to watch
Phase 2Untreated Adult Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-04-18 · NCT02835222 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma …Recruiting
Est. primary completion 2027-05-01 · NCT05333458 · CT.gov ↗
What to watch
Phase 1/2Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKLRecruiting
Est. primary completion 2027-05-30 · NCT06966154 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2MyelofibrosisRecruiting
Est. primary completion 2027-06 · NCT05980806 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma …Active not recruiting
Est. primary completion 2027-06-25 · NCT03147885 · CT.gov ↗
What to watch
Phase 1TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell TransplantationActive not recruiting
Est. primary completion 2027-06-30 · NCT07094464 · CT.gov ↗
What to watch
Phase 1/2Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated GlioblastomaRecruiting
Est. primary completion 2027-06-30 · NCT05432804 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-07 · NCT07479979 · CT.gov ↗
What to watch
Phase 2Lymphoma, Extranodal NK-T-CellNot yet recruiting
Est. primary completion 2027-07-01 · NCT06573138 · CT.gov ↗
What to watch
Phase 2LymphomaNot yet recruiting
Est. primary completion 2027-07-01 · NCT06573151 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Langerhans Cell Histiocytosis (LCH)Active not recruiting
Est. primary completion 2027-08-01 · NCT07204041 · CT.gov ↗
What to watch
September 2027 (3)
Early phase / not applicableLymphoma CnsRecruiting
Est. primary completion 2027-09-02 · NCT07191431 · CT.gov ↗
What to watch
Phase 1/2Malignant GliomaActive not recruiting
Est. primary completion 2027-09-30 · NCT05099003 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2027-09-30 · NCT06613035 · CT.gov ↗
What to watch
October 2027 (1)
Early phase / not applicableMyeloid TumorsNot yet recruiting
Est. primary completion 2027-10-01 · NCT07632170 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast CancersRecruiting
Est. primary completion 2027-11 · NCT05035745 · CT.gov ↗
What to watch
December 2027 (5)
Phase 2Extensive Stage Lung Small Cell CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07172412 · CT.gov ↗
What to watch
Phase 3Multiple MyelomaActive not recruiting
Est. primary completion 2027-12 · NCT06158841 · CT.gov ↗
What to watch
Phase 2Central Nervous System LymphomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07405255 · CT.gov ↗
What to watch
Phase 2Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-12-31 · NCT07437170 · CT.gov ↗
What to watch
Phase 2Extranodal NK/T-cell LymphomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07554482 · CT.gov ↗
What to watch
2028 (13)
January 2028 (4)
Phase 1/2Peripheral T-cell Lymphoma (PTCL)Not yet recruiting
Est. primary completion 2028-01 · NCT07706959 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaNot yet recruiting
Est. primary completion 2028-01-01 · NCT06744894 · CT.gov ↗
What to watch
Early phase / not applicableAML, Refractory, RelapsedRecruiting
Est. primary completion 2028-01-30 · NCT06265545 · CT.gov ↗
What to watch
February 2028 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-02 · NCT04661137 · CT.gov ↗
What to watch
Phase 2Light-chain Cardiac AmyloidosisNot yet recruiting
Est. primary completion 2028-02-01 · NCT07743957 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial TumorRecruiting
Est. primary completion 2028-02-17 · NCT06813079 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2NKTCLNot yet recruiting
Est. primary completion 2028-03-06 · NCT07574528 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2028-03-26 · NCT05530421 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1/2Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)Active not recruiting
Est. primary completion 2028-04-30 · NCT07779031 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07832227 · CT.gov ↗
What to watch
Phase 1/2B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS MetastasesRecruiting
Est. primary completion 2028-12-30 · NCT06552559 · CT.gov ↗
What to watch
Phase 2LymphomasRecruiting
Est. primary completion 2028-12-30 · NCT07002099 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2029-04-30 · NCT07200102 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid TumorRecruiting
Est. primary completion 2029-08-01 · NCT05985161 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2NK T-Cell LymphomaNot yet recruiting
Est. primary completion 2029-12-30 · NCT07276698 · CT.gov ↗
What to watch
2030 (2)
May 2030 (1)
Phase 2MyelofibrosisRecruiting
Est. primary completion 2030-05-24 · NCT07447817 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2030-08-28 · NCT05983276 · CT.gov ↗
What to watch
2034 (1)
June 2034 (1)
Phase 1/2Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma, Fibrosarcoma NOS, Myxofibrosarcoma …Recruiting
Est. primary completion 2034-06 · NCT06239272 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 June 2027FDA action datePDUFA date for the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗

Recent

17 November 2026Filing acceptedFDA accepts the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗
31 August 2026Filing submittedKaryopharm submits an sNDA to FDA for XPOVIO plus ruxolitinib in myelofibrosis (accelerated approval, Priority Review requested)
US, FDA · Karyopharm Therapeutics Inc. · Source ↗
30 July 2026Topline resultPhase 3 XPORT-EC-042 (NCT05611931) of selinexor maintenance in endometrial cancer did not meet its PFS primary endpoint
Global · Karyopharm Therapeutics Inc. · Source ↗
2 June 2026Topline resultSENTRY Phase 3 topline results were mixed
24 March 2026Topline resultPhase 3 SENTRY (NCT04562389) met its first co-primary endpoint (SVR35) and missed its second (Abs-TSS)
Global · Karyopharm Therapeutics Inc. · Source ↗
March 2026WithdrawalAccelerated approval in DLBCL voluntarily withdrawn at the FDA's request
US, FDA · Source ↗
16 December 2025ApprovalMalaysia approves XPOVIO (selinexor) sNDA for relapsed/refractory DLBCL
MY, NPRA · Source ↗
5 March 2025ApprovalXPOVIO approved in Indonesia
ID, BPOM · Source ↗
9 December 2024Topline resultBENCH Phase III primary analysis presented: primary endpoint met